A21 Development of an Nrf2-KEAP1 protein-protein disruptor for proof of concept
Alberto Bresciani(University of Bergamo), Larry Park(CHDI Foundation), Mariana Gallo(University of Parma), Daniele Moretti(University of Siena), M. D'AMICO(IRBM Science Park), Leticia Toledo Sherman(CHDI Foundation), Mauro Cerretani(IRBM Science Park), Celia Dominguez(CHDI Foundation), Alessia Santoprete(IRBM Science Park), Licia Tomei(IRBM Science Park), Paola Fezzardi(IRBM Science Park), Ignacio Munoz Sanjuan(CHDI Foundation), Sara Tambone(IRBM Science Park), Antonino Missineo(IRBM Science Park)
Cited by 2
Related Papers
Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease
|Journal of Medicinal Chemistry|2013|149
Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis
|Cell Death and Differentiation|2020|149
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
|Human Pathology|2009|139
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington’s disease
|Journal of Clinical Investigation|2019|101
Apoptosis: a general comment
|The FASEB Journal|1991|81